Damora Therapeutics (DMRA) Total Non-Current Liabilities (2019 - 2026)
Damora Therapeutics (DMRA) posted Total Non-Current Liabilities of $23.8 million for Q1 2026, up 18.67% on a QoQ basis from $20.1 million in Q4 2025, and up 1378.09% year-over-year from $1.6 million in Q1 2025.
Damora Therapeutics (DMRA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Damora Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $23.8 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 1378.09% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (up 1378.09% YoY) and the FY2025 annual result came in at $20.1 million, up 1495.07% from the prior year.
- Total Non-Current Liabilities was $23.8 million for Q1 2026 at Damora Therapeutics, up from $20.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $23.8 million in Q1 2026 and bottomed at $1.3 million in Q4 2024.
- A 3-year average of $8.7 million and a median of $2.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities jumped 1495.07% — and 2026, when it soared 1378.09%.
- Damora Therapeutics' Total Non-Current Liabilities stood at $1.3 million in 2024, then soared by 1495.07% to $20.1 million in 2025, then gained by 18.67% to $23.8 million in 2026.
- Business Quant data shows DMRA's Total Non-Current Liabilities at $23.8 million in Q1 2026, $20.1 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 23.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.81 Mn |
| Dec 31, 2025 | 20.07 Mn |
| Sep 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.69 Mn |
| Mar 31, 2025 | 1.61 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2020 | 8.87 Mn |
| Dec 31, 2019 | 8.14 Mn |